Phase 1 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have at least one tumour that can be measured using standard imaging guidelines.
- People who are generally able to carry out daily activities with little to no limitation (based on a standard health scoring system called ECOG, with a score of 0 or 1).
- For the dose-finding part of the trial: people who have any type of solid tumour that has been confirmed by a pathologist, and where no other treatment options are currently available.
- For the dose-expansion part of the trial: people who have been diagnosed with a specific type of kidney cancer called clear cell renal cell carcinoma (ccRCC), confirmed through tissue testing.
- People whose kidneys are functioning at a sufficient level (a kidney function measurement of 40 mL/min or above).
Who may not be able to join:
- People who have received a live vaccine (such as flu or chickenpox vaccines) within the 4 weeks before starting the trial treatment.
- People who have another significant heart, breathing, or other medical or mental health condition that could interfere with taking part in the trial or make the trial treatment unsafe.
- People who have had a serious injury or major surgery within 28 days before the first trial treatment dose.
- For the dose-expansion parts of the trial: people who have previously been treated with a type of drug called a HIF-2α inhibitor. For one specific treatment group involving casdatifan and cabozantinib: people who have previously received cabozantinib. For treatment groups involving casdatifan and zimberelimab (with or without ipilimumab): people who have previously received any systemic (whole-body) treatment while their cancer was present.
- People who have known psychiatric conditions or substance use disorders that would make it difficult to follow the requirements of the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Arcus Biosciences
Phone: +1-510-462-3330
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants with dose limiting toxicities (DLTs); Number of participants with adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.